Wordt geladen...
The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN
The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis share driver mutations that either activate the thrombopoietin receptor, MPL, or indirectly activate it through mutations in the gene for JAK2, its cognate tyrosine kinase. Paradoxically, although...
Bewaard in:
| Gepubliceerd in: | Front Oncol |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Media S.A.
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7987816/ https://ncbi.nlm.nih.gov/pubmed/33777803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.641613 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|